{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"neuronal-ceroid-lipofuscinosis-8-northern-epilepsy-variant","columns":[{"countQualifier":"Onset group unspecified","gene":"CLN8","key":"population-8bcadaddcce7d81f0919","label":"CLN8, Northern epilepsy entry","mondoId":"MONDO:0012391","onsetQualifier":null,"originColumnKey":"MONDO:0012391","originalViews":[{"key":"MONDO:0012391","label":"CLN8, Northern epilepsy entry","scopeLabel":"Genetic form","sourceScope":null}],"recordKeys":["00116d2926aa5e0f3ee9c6aa2acd42a428782573bae221e4288a32fe8d0e38aa","35e028dc7290aeaea4c78e66714beec5c85430b4e28b47afa6f1f58d9963e8b5","4879653c4a2a9c13053635980f80e9edeb8a082657f42869b284664fc7055fef","5d3c36b8c4df00d90ff850ae623648c928f870c915e6419eb0344bb3a62baed8","60f2d28326d2717af782e88560037a1faeab01b00f99383948f541c2d1eab2cb","687e6b0142d164ffea7d7630a0752d458924171aaf5fbe23fbb915fac3842d92","8e4e6f701a9eb8eaa04251c57e578e2834ee29936d6f834eb5884e1b8fec20df","9aa6dad12aeba0163840669a83237e99d05b4f8ba71a64a27c3be0bf12767a73","9b9f1f2fc55c3ea7a1c0e1e27e118482bcc462439a9d7743dac29550ddb58a0a","b87080d10f8e6ad46f8577646f1a8ead32a6ad6ef6c78ca74b1c15f5b9970e6f","e78825ba793569a41c57179475708269f02060b08f044041148e28aa427a4003","f59022cd11059fb4a5b8cf7ce61d02aa3ad47cb92c57c7c0971995029e30e434"],"recordQualifiers":{},"scopeLabel":"Genetic form","sourceIds":["OMIM:610003"],"sourceScope":null},{"gene":"","key":"population-34f190c8a2e818cec32c","label":"Northern epilepsy","mondoId":"MONDO:0012391","onsetQualifier":null,"originColumnKey":"MONDO:0012391/ORPHA:1947","originalViews":[{"key":"MONDO:0012391/ORPHA:1947","label":"Northern epilepsy","scopeLabel":"ORPHA:1947","sourceScope":"This column retains this exact native source population. It is not a pooled family estimate."}],"recordKeys":["00ad89dce742cfaaf514fd11c7f9630ecdf797ad3b746dd1e8317b128c2130bd","07fa39637c5b1c90972b70aeed94320a4ca17dd199e8fe0f00b239111d39b73d","0b7d92fe3ee5179d6b1a327ca4a09f4ac350f024fe112950ec07a053936fa6e1","0bf762cef5335d4678f6bbac7ed135eddddf1a264fedaec97a7bf06d7ec13d84","105ea1acb34a03195db90ec10fe93b8f3ba75e38e85a6a6b14cb0c3644555d85","1f7dba85a4bd298e2a0d8965cb99c026a44955a46975ce406b15a6e5c2bb9734","22b65ad02344f1e9537af2454807387445cddf06c9921948095b549d5f866ed6","28db20a737e784f91d8b8a12ea6addf73e029f24d6f225a3d3fed20ed178acd2","2ae6e4b2500752d3cadfc5d81ec8cda09dd1050383109af041fba39743355cfc","2b5c7a4745a388f28346e1faab904f4230b61376f5c227aa4d5fe6e78b886eda","2d0e851eb730f6debfd4eb056767f3306dc81227b4d86a434c53fcd6d7a98ac8","35fb4976c4e52b7f02bf1ee231927fb2448951b3e048ae3efa1c3d0eaff0f19b","39b688177ac095982953349d20b40f82a9f2faef18091b3c97558fbb27d9bf38","479aca3e11e89e6b299d54db2db0b84064197067ab67a0be55a83b09482bf1fa","5d0024a27e5bac3e94242ed5f6d65019c44a6442b21f136ff661da82cea6ba22","5d94956288a4ab981e4fe79b41a3d016f2ead5a34dd9d680b7d8aca8a43190f6","617ba00540c498587e11569f4b2766004bf075004215fd2c13272509b8cf98de","67e4ef673726203d90aefcdd10c2450b0f0f572c6f902d6d66b2e7a2e5372b58","743354fd5cdd9ff3cad26901f0576f56adf9776e73b78631ed21d0d0b6ea564e","7442a954be2e69d3dc119cce346c26c24995bf2511f6cbf2b5545653157772c1","75970e51081ab3344231171bd9f70324563124ff063ac8740009484d574b44c3","769774b956c9a6a5a547b18a25df3d4b8211dad584befd3f1fe364b9baec7aa1","7d70334ec87ccb442cebac512a0cfe2511579d7c60a265927f70bd9a83ce9431","7ef3c551d9e08f34efffaaa542eb83dc79525ed1649186204f62dee27e52d9ac","80f84bb8e44f1ac92c56b6f9669398559dbfe5abc8951fac69abb347a3153d27","8c538a631176b6c39e190605a3aaee8e9243182c1042cca87229f078748d8749","a1ff4ed91439627f5d85c4958f234448c034ad075865584d06d011052c61e140","b7f226ea0b8a8051eba8b6aafb885a5d4bf33b94ed93c14b56cb22e8a2d4efdf","b878830a51b0108ad73ca66fd50d52911a2936cc02620cdd4dde8d854d311184","b9ec06adfb75035f07c63785d39efff612e7c7fa21ae7422ac72080cc5f6da48","bd3ad84eace908a105359a331c1569bdbb3074469bb8b7fa9c194e334a1376cb","c0ef6beab39c34358a8dc8ee22229fb1dace69c7d20ca6e640271d88c24b4b87","c471a646fb260de425bd693f3f64a65439467d7d76a33209d6496e83e48ba647","c531d819cf87fa508f28e324a4adf71624d2e3d903227f0cda297f3d6aadf504","c5b7ec768bc43c3540eff7495eaaca32c92254f616168b6937332c5c4fd67f4d","d17ee1fba4bbb48719aad68d5590f6c65fdc6ab2871ceb082fc15b4d62285084","d28c050df1342f55d9025f73e5f87604c50f0ea1467a3f57bc6284635a534f4c","dd821d91bebc69a2dff031b845c6dd3ada858f12b1c722e1151cb2d8646c2040","f578fc1bdd7bbca62de6b63ea7dba678f85119ef96748eb60765e093f7050e79"],"recordQualifiers":{},"scopeLabel":"ORPHA:1947","sourceIds":["ORPHA:1947"],"sourceScope":"This column retains this exact native source population. It is not a pooled family estimate."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-8bcadaddcce7d81f0919","population-34f190c8a2e818cec32c"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0002167","HP:0030455","HP:0001251","HP:0000708","HP:0000729","HP:0002069","HP:0001272"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":51,"sourceGroups":{"omim":12,"orphanet":39}},"features":[{"hpoId":"HP:0002167","label":"Abnormal speech pattern","primary":true},{"hpoId":"HP:0030455","label":"Abnormality of pattern visual evoked potentials","primary":true},{"hpoId":"HP:0001251","label":"Ataxia","primary":true},{"hpoId":"HP:0000708","label":"Atypical behavior","primary":true},{"hpoId":"HP:0000729","label":"Autistic behavior","primary":true},{"hpoId":"HP:0002069","label":"Bilateral tonic-clonic seizure","primary":true},{"hpoId":"HP:0001272","label":"Cerebellar atrophy","primary":true},{"hpoId":"HP:0002059","label":"Cerebral atrophy","primary":false},{"hpoId":"HP:0002312","label":"Clumsiness","primary":false},{"hpoId":"HP:0100543","label":"Cognitive impairment","primary":false},{"hpoId":"HP:0003205","label":"Curvilinear intracellular accumulation of autofluorescent lipopigment storage material","primary":false},{"hpoId":"HP:0000750","label":"Delayed speech and language development","primary":false},{"hpoId":"HP:0000726","label":"Dementia","primary":false},{"hpoId":"HP:0003698","label":"Difficulty standing","primary":false},{"hpoId":"HP:0002015","label":"Dysphagia","primary":false},{"hpoId":"HP:0002353","label":"EEG abnormality","primary":false},{"hpoId":"HP:0011203","label":"EEG with abnormally slow frequencies","primary":false},{"hpoId":"HP:0011198","label":"EEG with generalized epileptiform discharges","primary":false},{"hpoId":"HP:0003208","label":"Fingerprint intracellular accumulation of autofluorescent lipopigment storage material","primary":false},{"hpoId":"HP:0002384","label":"Focal impaired awareness seizure","primary":false},{"hpoId":"HP:0002359","label":"Frequent falls","primary":false},{"hpoId":"HP:0002066","label":"Gait ataxia","primary":false},{"hpoId":"HP:0011471","label":"Gastrostomy tube feeding in infancy","primary":false},{"hpoId":"HP:0002123","label":"Generalized myoclonic seizure","primary":false},{"hpoId":"HP:0001263","label":"Global developmental delay","primary":false},{"hpoId":"HP:0030890","label":"Hyperintensity of cerebral white matter on MRI","primary":false},{"hpoId":"HP:0002540","label":"Inability to walk","primary":false},{"hpoId":"HP:0002074","label":"Increased neuronal autofluorescent lipopigment","primary":false},{"hpoId":"HP:0001249","label":"Intellectual disability","primary":false},{"hpoId":"HP:0003204","label":"Intracellular accumulation of autofluorescent lipopigment storage material","primary":false},{"hpoId":"HP:0000737","label":"Irritability","primary":false},{"hpoId":"HP:0002371","label":"Loss of speech","primary":false},{"hpoId":"HP:0001268","label":"Mental deterioration","primary":false},{"hpoId":"HP:0002333","label":"Motor deterioration","primary":false},{"hpoId":"HP:0033044","label":"Motor regression","primary":false},{"hpoId":"HP:0000543","label":"Optic disc pallor","primary":false},{"hpoId":"HP:0000529","label":"Progressive visual loss","primary":false},{"hpoId":"HP:0000711","label":"Restlessness","primary":false},{"hpoId":"HP:0001250","label":"Seizure","primary":false},{"hpoId":"HP:0002510","label":"Spastic tetraplegia","primary":false},{"hpoId":"HP:0012690","label":"T2 hypointense thalamus","primary":false},{"hpoId":"HP:0000550","label":"Undetectable electroretinogram","primary":false},{"hpoId":"HP:0002317","label":"Unsteady gait","primary":false},{"hpoId":"HP:0003657","label":"Vascular granular osmiophilic material deposition","primary":false},{"hpoId":"HP:0000505","label":"Visual impairment","primary":false}],"ledeHtml":"Progressive epilepsy-intellectual disability syndrome, Finnish type is a rare condition that affects the nervous system. Some affected people may also experience decreased visual acuity. Progressive epilepsy-intellectual disability syndrome, Finnish type is caused by changes in the CLN8 gene and is inherited in an autosomal recessive manner.","mondoId":"MONDO:0012391","node":{"canonicalSlug":"neuronal-ceroid-lipofuscinosis-8-northern-epilepsy-variant","comparisons":[{"documentSha256":"feab7132c1e6efa19316faa9c5b975a6a6317da700f12b5b4c059a18eda6d069","key":"legacy-cln","kind":"legacy","label":"CLN / Batten disease","memberIds":["MONDO:0008083","MONDO:0008767","MONDO:0008768","MONDO:0008769","MONDO:0009744","MONDO:0009745","MONDO:0010830","MONDO:0011144","MONDO:0012391","MONDO:0012414","MONDO:0012588","MONDO:0012721","MONDO:0013866","MONDO:0014147","MONDO:0016295"],"mondoId":"MONDO:0016295","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/cln.feab7132c1e6efa19316faa9c5b975a6a6317da700f12b5b4c059a18eda6d069.json"},{"documentSha256":"df7e5010cb40de30aba1b0d10ff00b9c8a49865234f6a0ea186c9a1493e9aae3","key":"expanded-cln","kind":"expanded","label":"CLN / Batten disease","memberIds":["MONDO:0008083","MONDO:0008767","MONDO:0008768","MONDO:0008769","MONDO:0009744","MONDO:0009745","MONDO:0010830","MONDO:0011144","MONDO:0012188","MONDO:0012391","MONDO:0012414","MONDO:0012588","MONDO:0012721","MONDO:0013866","MONDO:0014147","MONDO:0016295","MONDO:0017809","MONDO:0019260","MONDO:0019261","MONDO:0019262","MONDO:0030947","MONDO:0850001"],"mondoId":"MONDO:0016295","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/node-comparison-df7e5010cb40de30aba1.df7e5010cb40de30aba1b0d10ff00b9c8a49865234f6a0ea186c9a1493e9aae3.json"}],"contexts":[{"causes":["Mutations in the CLN8 gene cause CLN8 disease. The CLN8 gene provides instructions for making a protein whose function is not well understood. The CLN8 protein is thought to play a role in moving materials in and out of a cell structure called the endoplasmic reticulum. The endoplasmic reticulum is involved in protein production, processing, and transport to different parts of the cell. The CLN8 protein may also play a role in helping the endoplasmic reticulum regulate levels of fats (lipids) in cells. In certain cells, including nerve cells, the CLN8 protein is thought to be active outside of the endoplasmic reticulum, but its function is unknown.","A specific mutation in the CLN8 gene is found in all individuals in northern Finland with the less-severe form of CLN8 disease. This mutation probably leads to production of a protein with reduced function. Because there is likely still some normal function of the CLN8 protein, features of this form are less severe compared to other cases of CLN8 disease. Affected individuals have a reduction in the levels of certain lipids in the brain, likely due to a decrease in CLN8 protein activity, but the effect of this reduction is unclear. Individuals with this form of CLN8 disease have mild brain abnormalities resulting from nerve cell death in the brain, but the cause of the cell death is unknown. Unlike other forms of NCL that result in the accumulation of proteins and other substances in cells, contributing to cell death, the less-severe form of CLN8 disease is associated with very little buildup in cells.","Some CLN8 gene mutations are thought to drastically reduce the function of the CLN8 protein. Other mutations likely impair transport of the protein to the endoplasmic reticulum, so that it cannot perform its function. It is unclear how a loss or reduction of CLN8 protein leads to the signs and symptoms of CLN8 disease. Unlike the less-severe form, in the more-severe form of CLN8 disease, proteins and other substances accumulate in cell structures called lysosomes. While accumulations of these substances occur in cells throughout the body, nerve cells appear to be particularly vulnerable to damage caused by the abnormal cell materials; however, it is unclear how mutations in the CLN8 gene are involved in this buildup. Widespread loss of nerve cells in CLN8 disease leads to the neurological signs and symptoms and, in the case of the more-severe form, early death."],"causesUrl":"https://medlineplus.gov/genetics/condition/cln8-disease/#causes","contentForm":"summary","matchMethod":"reviewed-binding","name":"CLN8 disease","paragraphs":["CLN8 disease is an inherited disorder that varies in severity and primarily affects the nervous system. The condition is generally separated into less-severe and more-severe forms, based on the types of signs and symptoms that develop and life expectancy.","The less-severe form of CLN8 disease, sometimes referred to as Northern epilepsy, is characterized by recurrent seizures (epilepsy) and a decline in intellectual function that begins between ages 5 and 10. The seizures in this form may be resistant to treatment and are often the generalized tonic-clonic type, which involve muscle rigidity, convulsions, and loss of consciousness. Some people with this form of CLN8 disease also experience partial seizures, which do not cause a loss of consciousness. The seizures occur approximately one to two times per month until adolescence; by early adulthood the frequency decreases to about four to six times per year. By middle age, seizures become even less frequent. In addition to seizures, affected individuals experience a gradual decline in intellectual function and develop problems with coordination and balance. Vision problems may occur in early to mid-adulthood. Individuals with the less-severe form of CLN8 disease often live into late adulthood.","The more-severe form of CLN8 disease typically begins between ages 2 and 7.The seizures in this form involve uncontrollable muscle jerks (myoclonic epilepsy). Individuals with the more-severe form have a more pronounced decline in intellectual function and usually lose the ability to speak. Vision loss is also common. People with this form of CLN8 disease have increasing difficulty walking and coordinating movements (ataxia), eventually becoming immobile. Individuals with the more-severe form of CLN8 disease usually survive only into late childhood or adolescence.","CLN8 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), which may also be collectively referred to as Batten disease. All these disorders affect the nervous system and typically cause worsening problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause. Each disease type is given the designation \"CLN,\" meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype."],"reviewed":"2016-12","scope":"broader","scopeNote":"The CLN8 article discusses both Northern epilepsy and other CLN8 presentations. This table retains the Northern epilepsy source entries only.","source":"MedlinePlus","sourceRelease":"2026-10-01","upstream":"MedlinePlus Genetics","url":"https://medlineplus.gov/genetics/condition/cln8-disease"}],"lifecycle":"active","narrative":{"causes":[],"contentForm":"summary","independentCorroborationEstablished":false,"matchMethod":"automatic-identity-and-attribution","name":"Neuronal ceroid lipofuscinosis 8 northern epilepsy variant","originalSourceId":"ORPHA:1947","paragraphs":["Progressive epilepsy-intellectual disability syndrome, Finnish type is a rare condition that affects the nervous system. Some affected people may also experience decreased visual acuity. Progressive epilepsy-intellectual disability syndrome, Finnish type is caused by changes in the CLN8 gene and is inherited in an autosomal recessive manner."],"rawAttribution":"MONDO:0012391","reviewed":null,"scope":"exact","source":"GARD","sourceRelease":"2026-10-25T03:39:07Z","upstream":"GARD:0004010","url":"https://rarediseases.info.nih.gov/diseases/4010"},"ownColumnKeys":["population-8bcadaddcce7d81f0919","population-34f190c8a2e818cec32c"],"publication":"published","relationships":[{"kind":"parent","label":"neuronal ceroid lipofuscinosis 8","mondoId":"MONDO:0010830","slug":"neuronal-ceroid-lipofuscinosis-8"},{"kind":"parent","label":"monogenic epilepsy","mondoId":"MONDO:0015653","slug":null},{"kind":"parent","label":"syndromic dyslipidemia","mondoId":"MONDO:0015905","slug":null},{"kind":"parent","label":"progressive myoclonus epilepsy","mondoId":"MONDO:0020074","slug":"progressive-myoclonus-epilepsy"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[{"reason":"multiple-identity-targets","source":"MedlinePlus","url":"https://medlineplus.gov/genetics/condition/cln8-disease"}],"translation":"published"},"records":[{"frequencyKind":"reported","key":"00116d2926aa5e0f3ee9c6aa2acd42a428782573bae221e4288a32fe8d0e38aa","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:610003","disease_name":"Ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002059","is_excluded":false,"label":"Cerebral atrophy","onset_id":null,"reference":"OMIM:610003","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"00ad89dce742cfaaf514fd11c7f9630ecdf797ad3b746dd1e8317b128c2130bd","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0002059","is_excluded":false,"label":"Cerebral atrophy","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"07fa39637c5b1c90972b70aeed94320a4ca17dd199e8fe0f00b239111d39b73d","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000726","is_excluded":false,"label":"Dementia","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"0b7d92fe3ee5179d6b1a327ca4a09f4ac350f024fe112950ec07a053936fa6e1","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0002066","is_excluded":false,"label":"Gait ataxia","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"0bf762cef5335d4678f6bbac7ed135eddddf1a264fedaec97a7bf06d7ec13d84","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001250","is_excluded":false,"label":"Seizure","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"105ea1acb34a03195db90ec10fe93b8f3ba75e38e85a6a6b14cb0c3644555d85","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0100543","is_excluded":false,"label":"Cognitive impairment","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"1f7dba85a4bd298e2a0d8965cb99c026a44955a46975ce406b15a6e5c2bb9734","raw":{"aspect":"P","body_system":"eye","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000550","is_excluded":false,"label":"Undetectable electroretinogram","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"22b65ad02344f1e9537af2454807387445cddf06c9921948095b549d5f866ed6","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0002123","is_excluded":false,"label":"Generalized myoclonic seizure","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"28db20a737e784f91d8b8a12ea6addf73e029f24d6f225a3d3fed20ed178acd2","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000729","is_excluded":false,"label":"Autistic behavior","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"2ae6e4b2500752d3cadfc5d81ec8cda09dd1050383109af041fba39743355cfc","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002384","is_excluded":false,"label":"Focal impaired awareness seizure","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"2b5c7a4745a388f28346e1faab904f4230b61376f5c227aa4d5fe6e78b886eda","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002015","is_excluded":false,"label":"Dysphagia","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"2d0e851eb730f6debfd4eb056767f3306dc81227b4d86a434c53fcd6d7a98ac8","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002359","is_excluded":false,"label":"Frequent falls","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"35e028dc7290aeaea4c78e66714beec5c85430b4e28b47afa6f1f58d9963e8b5","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:610003","disease_name":"Ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002312","is_excluded":false,"label":"Clumsiness","onset_id":null,"reference":"OMIM:610003","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"35fb4976c4e52b7f02bf1ee231927fb2448951b3e048ae3efa1c3d0eaff0f19b","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000750","is_excluded":false,"label":"Delayed speech and language development","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"39b688177ac095982953349d20b40f82a9f2faef18091b3c97558fbb27d9bf38","raw":{"aspect":"P","body_system":"eye","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000505","is_excluded":false,"label":"Visual impairment","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"479aca3e11e89e6b299d54db2db0b84064197067ab67a0be55a83b09482bf1fa","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0003204","is_excluded":false,"label":"Intracellular accumulation of autofluorescent lipopigment storage material","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"4879653c4a2a9c13053635980f80e9edeb8a082657f42869b284664fc7055fef","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:610003","disease_name":"Ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001272","is_excluded":false,"label":"Cerebellar atrophy","onset_id":null,"reference":"OMIM:610003","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"5d0024a27e5bac3e94242ed5f6d65019c44a6442b21f136ff661da82cea6ba22","raw":{"aspect":"P","body_system":"eye","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000543","is_excluded":false,"label":"Optic disc pallor","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"5d3c36b8c4df00d90ff850ae623648c928f870c915e6419eb0344bb3a62baed8","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:610003","disease_name":"Ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000711","is_excluded":false,"label":"Restlessness","onset_id":null,"reference":"OMIM:610003","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"5d94956288a4ab981e4fe79b41a3d016f2ead5a34dd9d680b7d8aca8a43190f6","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001251","is_excluded":false,"label":"Ataxia","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"60f2d28326d2717af782e88560037a1faeab01b00f99383948f541c2d1eab2cb","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:610003","disease_name":"Ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0001268","is_excluded":false,"label":"Mental deterioration","onset_id":null,"reference":"OMIM:610003","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"617ba00540c498587e11569f4b2766004bf075004215fd2c13272509b8cf98de","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0003205","is_excluded":false,"label":"Curvilinear intracellular accumulation of autofluorescent lipopigment storage material","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"67e4ef673726203d90aefcdd10c2450b0f0f572c6f902d6d66b2e7a2e5372b58","raw":{"aspect":"P","body_system":"eye","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000529","is_excluded":false,"label":"Progressive visual loss","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"687e6b0142d164ffea7d7630a0752d458924171aaf5fbe23fbb915fac3842d92","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:610003","disease_name":"Ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002074","is_excluded":false,"label":"Increased neuronal autofluorescent lipopigment","onset_id":null,"reference":"OMIM:610003","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"743354fd5cdd9ff3cad26901f0576f56adf9776e73b78631ed21d0d0b6ea564e","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001272","is_excluded":false,"label":"Cerebellar atrophy","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"7442a954be2e69d3dc119cce346c26c24995bf2511f6cbf2b5545653157772c1","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0002510","is_excluded":false,"label":"Spastic tetraplegia","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"75970e51081ab3344231171bd9f70324563124ff063ac8740009484d574b44c3","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000708","is_excluded":false,"label":"Atypical behavior","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"769774b956c9a6a5a547b18a25df3d4b8211dad584befd3f1fe364b9baec7aa1","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001249","is_excluded":false,"label":"Intellectual disability","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"7d70334ec87ccb442cebac512a0cfe2511579d7c60a265927f70bd9a83ce9431","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0002317","is_excluded":false,"label":"Unsteady gait","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"7ef3c551d9e08f34efffaaa542eb83dc79525ed1649186204f62dee27e52d9ac","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0003208","is_excluded":false,"label":"Fingerprint intracellular accumulation of autofluorescent lipopigment storage material","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"80f84bb8e44f1ac92c56b6f9669398559dbfe5abc8951fac69abb347a3153d27","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0030890","is_excluded":false,"label":"Hyperintensity of cerebral white matter on MRI","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"8c538a631176b6c39e190605a3aaee8e9243182c1042cca87229f078748d8749","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0002540","is_excluded":false,"label":"Inability to walk","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"8e4e6f701a9eb8eaa04251c57e578e2834ee29936d6f834eb5884e1b8fec20df","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:610003","disease_name":"Ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002384","is_excluded":false,"label":"Focal impaired awareness seizure","onset_id":null,"reference":"OMIM:610003","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"9aa6dad12aeba0163840669a83237e99d05b4f8ba71a64a27c3be0bf12767a73","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:610003","disease_name":"Ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002353","is_excluded":false,"label":"EEG abnormality","onset_id":null,"reference":"OMIM:610003","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"9b9f1f2fc55c3ea7a1c0e1e27e118482bcc462439a9d7743dac29550ddb58a0a","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:610003","disease_name":"Ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001249","is_excluded":false,"label":"Intellectual disability","onset_id":null,"reference":"OMIM:610003","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"a1ff4ed91439627f5d85c4958f234448c034ad075865584d06d011052c61e140","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0033044","is_excluded":false,"label":"Motor regression","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"b7f226ea0b8a8051eba8b6aafb885a5d4bf33b94ed93c14b56cb22e8a2d4efdf","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0002167","is_excluded":false,"label":"Abnormal speech pattern","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"b87080d10f8e6ad46f8577646f1a8ead32a6ad6ef6c78ca74b1c15f5b9970e6f","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:610003","disease_name":"Ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003205","is_excluded":false,"label":"Curvilinear intracellular accumulation of autofluorescent lipopigment storage material","onset_id":null,"reference":"OMIM:610003","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"b878830a51b0108ad73ca66fd50d52911a2936cc02620cdd4dde8d854d311184","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0002312","is_excluded":false,"label":"Clumsiness","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"b9ec06adfb75035f07c63785d39efff612e7c7fa21ae7422ac72080cc5f6da48","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001263","is_excluded":false,"label":"Global developmental delay","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"bd3ad84eace908a105359a331c1569bdbb3074469bb8b7fa9c194e334a1376cb","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0003657","is_excluded":false,"label":"Vascular granular osmiophilic material deposition","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"c0ef6beab39c34358a8dc8ee22229fb1dace69c7d20ca6e640271d88c24b4b87","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0002371","is_excluded":false,"label":"Loss of speech","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"c471a646fb260de425bd693f3f64a65439467d7d76a33209d6496e83e48ba647","raw":{"aspect":"P","body_system":"eye","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0030455","is_excluded":false,"label":"Abnormality of pattern visual evoked potentials","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"c531d819cf87fa508f28e324a4adf71624d2e3d903227f0cda297f3d6aadf504","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0003698","is_excluded":false,"label":"Difficulty standing","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"c5b7ec768bc43c3540eff7495eaaca32c92254f616168b6937332c5c4fd67f4d","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0002333","is_excluded":false,"label":"Motor deterioration","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"d17ee1fba4bbb48719aad68d5590f6c65fdc6ab2871ceb082fc15b4d62285084","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0011203","is_excluded":false,"label":"EEG with abnormally slow frequencies","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"d28c050df1342f55d9025f73e5f87604c50f0ea1467a3f57bc6284635a534f4c","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0011198","is_excluded":false,"label":"EEG with generalized epileptiform discharges","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"dd821d91bebc69a2dff031b845c6dd3ada858f12b1c722e1151cb2d8646c2040","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0012690","is_excluded":false,"label":"T2 hypointense thalamus","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"e78825ba793569a41c57179475708269f02060b08f044041148e28aa427a4003","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:610003","disease_name":"Ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002069","is_excluded":false,"label":"Bilateral tonic-clonic seizure","onset_id":null,"reference":"OMIM:610003","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"f578fc1bdd7bbca62de6b63ea7dba678f85119ef96748eb60765e093f7050e79","raw":{"aspect":"P","body_system":"digestive","disease_id":"ORPHA:1947","disease_name":"Northern epilepsy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0011471","is_excluded":false,"label":"Gastrostomy tube feeding in infancy","onset_id":null,"reference":"ORPHA:1947","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"f59022cd11059fb4a5b8cf7ce61d02aa3ad47cb92c57c7c0971995029e30e434","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:610003","disease_name":"Ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0000737","is_excluded":false,"label":"Irritability","onset_id":null,"reference":"OMIM:610003","source_release":"2026-06-23"},"sourceGroups":["omim"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/4010\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0012391\" rel=\"noreferrer\">MONDO</a></p><p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/cln8-disease\" rel=\"noreferrer\">MedlinePlus</a> · The CLN8 article discusses both Northern epilepsy and other CLN8 presentations. This table retains the Northern epilepsy source entries only.</p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-identity-and-attribution</dd><dt>Upstream attribution</dt><dd>GARD:0004010</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Progressive epilepsy-intellectual disability syndrome, Finnish type is a rare condition that affects the nervous system. Some affected people may also experience decreased visual acuity. Progressive epilepsy-intellectual disability syndrome, Finnish type is caused by changes in the CLN8 gene and is inherited in an autosomal recessive manner.</p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/4010\" rel=\"noreferrer\">GARD</a></p>","key":"overview","title":"Overview"},{"bodyHtml":"<p>This source describes a broader group, rather than this exact condition.</p><p>CLN8 disease is an inherited disorder that varies in severity and primarily affects the nervous system. The condition is generally separated into less-severe and more-severe forms, based on the types of signs and symptoms that develop and life expectancy.</p><p>The less-severe form of CLN8 disease, sometimes referred to as Northern epilepsy, is characterized by recurrent seizures (epilepsy) and a decline in intellectual function that begins between ages 5 and 10. The seizures in this form may be resistant to treatment and are often the generalized tonic-clonic type, which involve muscle rigidity, convulsions, and loss of consciousness. Some people with this form of CLN8 disease also experience partial seizures, which do not cause a loss of consciousness. The seizures occur approximately one to two times per month until adolescence; by early adulthood the frequency decreases to about four to six times per year. By middle age, seizures become even less frequent. In addition to seizures, affected individuals experience a gradual decline in intellectual function and develop problems with coordination and balance. Vision problems may occur in early to mid-adulthood. Individuals with the less-severe form of CLN8 disease often live into late adulthood.</p><p>The more-severe form of CLN8 disease typically begins between ages 2 and 7.The seizures in this form involve uncontrollable muscle jerks (myoclonic epilepsy). Individuals with the more-severe form have a more pronounced decline in intellectual function and usually lose the ability to speak. Vision loss is also common. People with this form of CLN8 disease have increasing difficulty walking and coordinating movements (ataxia), eventually becoming immobile. Individuals with the more-severe form of CLN8 disease usually survive only into late childhood or adolescence.</p><p>CLN8 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), which may also be collectively referred to as Batten disease. All these disorders affect the nervous system and typically cause worsening problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause. Each disease type is given the designation &quot;CLN,&quot; meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype.</p><p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/cln8-disease\" rel=\"noreferrer\">MedlinePlus</a> · The CLN8 article discusses both Northern epilepsy and other CLN8 presentations. This table retains the Northern epilepsy source entries only.</p>","key":"context-0","title":"Broader context: CLN8 disease"}],"sharedSources":[],"slug":"neuronal-ceroid-lipofuscinosis-8-northern-epilepsy-variant","sourceDocuments":[{"name":"GARD: Neuronal ceroid lipofuscinosis 8 northern epilepsy variant","reviewed":null,"source_release":"2026-10-25T03:39:07Z","url":"https://rarediseases.info.nih.gov/diseases/4010"},{"name":"MONDO: neuronal ceroid lipofuscinosis 8 northern epilepsy variant","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0012391"},{"name":"MedlinePlus: CLN8 disease","reviewed":"2016-12","source_release":"2026-10-01","url":"https://medlineplus.gov/genetics/condition/cln8-disease"}],"sourceNote":"","synonyms":["ceroid lipofuscinosis neuronal 8","CLN8","CLN8 disease, EPMR (subtype)","CLN8 disease, late infantile (subtype)","CLN8 disease, Northern epilepsy variant","early onset familial encephalopathy with neuroserpin inclusion bodies","epilepsy mental deterioration Finnish type","epilepsy, progressive, with mental retardation","EPMR","NCL, Northern epilepsy variant","neuronal ceroid lipofuscinosis 8","neuronal ceroid lipofuscinosis, Northern epilepsy variant","Northern epilepsy","progressive epilepsy - intellectual disability, Finnish type","progressive epilepsy with intellectual disability, northern epilepsy","progressive epilepsy-intellectual disability syndrome, Finnish type","progressive myoclonic epilepsy with neuroserpin inclusion bodies"],"takeawayHtml":"","title":"neuronal ceroid lipofuscinosis 8 northern epilepsy variant"},"schemaVersion":1}
